# Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct07025174/  
OnCo record `nct07025174` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine, cisplatin, oxaliplatin and other drugs in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital of Zhejiang University, now recruiting.

## Summary

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer is a phase 2, randomised interventional study registered as NCT07025174 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 60 participants, started 2025-06-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib, Oxaliplatin + 5-Fluorouracil/Leucovorin. Conditions listed: Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SAIB
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07025174
- Phase: 2
- Setting: Evaluation of the Effect of Sequential Anti-angiogenic Therapy Following Immune Therapy Progression on Survival in Patients With Advanced Biliary Tract Malignancies: A Randomized, Multi-center, Exploratory Clinical Study
- Sponsor: First Affiliated Hospital of Zhejiang University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07025174: https://clinicaltrials.gov/study/NCT07025174

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07025174.json